Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders

Trial Profile

A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Attention deficit and disruptive behaviour disorders; Attention-deficit hyperactivity disorder; Autistic disorder; Bipolar I disorders; CNS disorders; Conduct disorder
  • Focus Pharmacokinetics
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 11 Jun 2018 Status changed from recruiting to completed.
    • 28 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 29 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top